-
Mashup Score: 0Clinical implications of neoadjuvant immunotherapy in CSCC - 1 month(s) ago
Charlotte Zuur, Leiden University Medical Center, Leiden, The Netherlands, discusses the clinical implications of the MATISSE trial (NCT02760498) for patients with cutaneous squamous cell carcinoma (CSCC). The trial results principally evaluated whether patients with a deep response to neoadjuvant immunotherapy might be spared intensive standard-of-care surgery and radiotherapy. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
7500 Background: The Bruton’s tyrosine kinase inhibitor (BTKi) ibrutinib +/- anti-CD20 antibody obinutuzumab (IO) is a standard frontline regimen for older adults with CLL. BTKi alone do not often lead to complete response (CR) or undetectable minimal residual disease (uMRD), thus are given indefinitely. Smaller trials showed that IO plus venetoclax (IVO) can induce uMRD CRs which may allow successful discontinuation. Methods: Alliance for Clinical Trials in Oncology A041702 is a multicenter trial designed to evaluate if IVO with response-guided discontinuation of I improves progression free survival (PFS) versus IO with indefinite I in treatment-naïve, older CLL pts. IO is given in standard fashion, and in the IVO arm V is added at C3D1 and continued until C14D28. After 14 cycles, pts undergo response evaluation including CT scans and bone marrow biopsy with central MRD assessment by flow cytometry. Pts in IVO arm with uMRD CR discontinue I; all others continue I until progression or
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Results of a phase 3 study of IVO vs IO for previously untreated older Pts w/ chronic lymphocytic leukemia (CLL) & impact of #COVID19 (@ALLIANCE_org A041702) - Woyach et al. #ASCO23 Abstract 7500 https://t.co/g5ExNiqWC6 #NCT03737981 #CLLsm #leusm #geriheme #COVID19nCancer
-
-
Mashup Score: 2Program Guide – ASCO Meeting Program Guide - 1 month(s) ago
Jennifer M. Ahlstrom HealthTree Foundation, Lehi, UT Jennifer M. Ahlstrom, Dee Lin, Nathan W. Sweeney, Bingcao Wu, Katharine Gries, Nina Kim, Saurabh Patel, Douglas W. Sborov, Jesus G. Berdeja, Larry D. Anderson, Jr, Jinhai Huo, Jay R Hydren HealthTree Foundation, Lehi, UT, Janssen Scientific Affairs, LLC, Horsham, PA, Janssen Global Services, LLC, Raritan, NJ, Janssen US Oncology Medical Affairs, Horsham, PA, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, Sarah Cannon Research
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Patient perspectives on BCMA-targeted therapies for multiple myeloma: A survey conducted in a patient advocacy group [@HealthtreeMM] - @AhlstromJenny et al. #ASCO23 Abstract 2582 https://t.co/JqM8VqmgcV #mmsm #CARTcell #ImmunoOnc HT @RahulBanerjeeMD
-
-
Mashup Score: 2Metabolomic Differences: Young Onset (yoCRC) vs. Average Onset (aoCRC) Colorectal Cancer - 2 month(s) ago
Listen as Dr. Kamath talks about the challenges associated with early detection, the evolving landscape of screening guidelines, potential contributing factors to the rise of yoCRC, and the role of metabolomics in unraveling the complexities of colorectal cancer.
Source: my.clevelandclinic.orgCategories: Latest Headlines, Oncologists1Tweet-
Tune in to this week's episode of the @CleClinicMD, Cancer Advances #podcast where I discuss our #ASCO23 study exploring metabolomic differences between young-onset CRC and average-onset colorectal cancer #CleClinicCancer https://t.co/giNq8nXliT @aakonc @ThejusJay
-
-
Mashup Score: 0
Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, comments on results by age in the Phase III monarchE trial (NCT03155997) of adjuvant abemaciclib combined with endocrine therapy in patients with high-risk early breast cancer. Patients aged 65 years or over had survival outcomes similar to those who are younger. Safety and tolerability were also comparable, and dose reduction is additionally possible, reducing the rate of discontinuation. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to see further updates from #monarchE at #ESMO23. The below interview was updated findings by age presented at this past #ASCO23. #bcsm #CDKi #abemaciclib @SarahCannonDocs Published by @VJOncology https://t.co/qWwGSuAEXA
-
-
Mashup Score: 51
KEYTRUDA® (pembrolizumab) is the first anti-PD-1 therapy to demonstrate statistically significant improvement in OS as a neoadjuvant and adjuvant treatment versus pre-operative chemotherapy for NSCLC Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB (T3-4N2) non-small cell lung cancer (NSCLC) met its dual primary endpoint of overall survival (OS). At a pre-specified interim analysis, KEYTRUDA plus chemotherapy before surgery (neoadjuvant), followed by resection and KEYTRUDA as a single agent after surgery (adjuvant), demonstrated a statistically significant and clinically meaningful improvement in OS compared to neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in these patients. The safety profile of KEYTRUDA was consistent with that observed in previously
Source: www.merck.comCategories: Hem/Oncs, Latest HeadlinesTweet-
JUST IN: KEYNOTE-671 OS + for EFS AND OS!!!! -NSCLC Stage II, IIIA or IIIB (T3-4N2) -Pembrolizumab is the first PD1 drug with OS in a perioperative setting! -Initially presented at #ASCO23 -Update at #ESMO23 https://t.co/rvGAQCu1yI @OncoAlert @myESMO @OncBrothers https://t.co/unbjYU8Atv https://t.co/vGyoOx3Oh4
-
🔥@OncoAlert Hot off the press Merck announces #KEYNOTE671 trial, #Neoadjuvant #Pembrolizumab (vs placebo) + chemo followed by #Adjuvant pembro (vs placebo) in pts with resectable stage II,IIIA or IIIB #NSCLC meets primary endpoint of #OverallSurvival. 👇🏼 https://t.co/gJtIzuB4xV https://t.co/CPDSHjQwOg
-
-
Mashup Score: 0
Natalie Vokes, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the EMPOWER-Lung 1 trial (NCT03088540), which investigated cemiplimab versus chemotherapy in patients with advanced, PD-L1-high non-small-cell lung cancer (NSCLC). The aim of the study was to assess the use of circulating tumor DNA (ctDNA) dynamics to understand immunotherapy responses. A clear bimodal distribution was witnessed in the immunotherapy cohort. In the chemotherapy cohort, many patients ctDNA reduced, but there was markedly less complete clearance. Patients who had a complete clearance of ctDNA had better long-term outcomes in terms of progression-free survival (PFS) and overall survival (OS). In terms of radiographic response assessments, dynamics correlated with either partial response or progressive disease. However, patients with stable disease either saw a rise or a fall in ctDNA levels. These patients could be categorized based on their ctDNA levels. Therefore, this study high
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@NIVokes of @MDAndersonNews reveals how circulating tumor DNA can help predict immunotherapy responses in PD-L1-high #NSCLC: ➡️https://t.co/ojdSlCQfXo #ASCO23 #LCSM #LungCancer #ImmunoOnc
-
-
Mashup Score: 0AI biomarker predicts benefit of long-term ADT in prostate cancer - 2 month(s) ago
Andrew J. Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, shares an overview of a study aiming to development and validate an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple Phase III NRG/RTOG trials.The researchers utilized digitized pre-treatment prostate biopsy slides from multiple phase III trials and trained an artificial intelligence (AI)-derived biomarker to predict the differential benefit of long-term (LT) ADT on distant metastasis (DM). The biomarker was then validated on a separate trial. Results showed that the AI biomarker accurately predicted the benefit of LTADT, allowing for personalized treatment decisions. The biomarker identified subgroups of patients who could derive similar benefits with short-term ADT, avoiding unnecessary side effects. This study demonstrates the potential of AI-derived biomarkers in guiding ADT durati
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥@AarmstrongDuke of @DukeCancer discusses AI's role in personalizing prostate cancer treatment, using digital pathology for better outcomes: ➡️https://t.co/N1n3gb9qcS #ASCO23 #Oncology
-
-
Mashup Score: 0
The HER2-targeting bispecific antibody zanidatamab generated rapid and durable responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer previously treated with gemcitabine, investigators from the global phase IIb HERIZON-BTC-01 study reported at the 2023 ASCO Annual Meeting. 1 The findings were simultaneously published in The Lancet Oncology. 2 HER2 is overexpressed or amplified in a subset of biliary tract cancer, and zanidatamab simultaneously targets
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
More on Biliary Tract Cancer From ASCO 2023: Focus on Zanidatamab https://t.co/tnwvXLcfZp #hpbcsm #biliarytractcancer #ASCO23 #oncology
-
-
Mashup Score: 0
The addition of the monoclonal antibody atezolizumab to the tyrosine kinase inhibitor cabozantinib failed to improve progression-free survival and overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma (previously treated with an immune checkpoint inhibitor) in the phase III CONTACT-03 trial. 1 The results of this study were published in The Lancet to coincide with the presentation at the 2023 ASCO Annual Meeting. 2 According to central review, median progression-free
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
More on Renal Cell Carcinoma From ASCO 2023: Focus on Atezolizumab Plus Cabozantinib vs Cabozantinib Alone https://t.co/Dr4uputNa1 #RCC #kcsm #kidneycancer #oncology #ASCO23
-
Charlotte Zuur from @LUMC_Leiden sheds light on the MATISSE trial's impact, offering potential alternatives to intensive treatments for cutaneous squamous cell carcinoma: ➡️https://t.co/T0RD9RzpWu⬅️ #ASCO23 #CTSM #SkcSM